| Attention deficit hyperactivity disorder
Dyanavel XR vs Jornay PM
Side-by-side clinical, coverage, and cost comparison for attention deficit hyperactivity disorder.Deep comparison between: Dyanavel Xr vs Jornay Pm with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJornay Pm has a higher rate of injection site reactions vs Dyanavel Xr based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Jornay Pm but not Dyanavel Xr, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Dyanavel Xr
Jornay Pm
At A Glance
Oral
Once daily
CNS stimulant
Oral
Daily
CNS stimulant
Indications
- Attention deficit hyperactivity disorder
- Attention deficit hyperactivity disorder
Dosing
Attention deficit hyperactivity disorder Starting dose 2.5 mg or 5 mg once daily in the morning; may increase by 2.5-10 mg per day every 4-7 days based on clinical response; maximum 20 mg once daily.
Attention deficit hyperactivity disorder 20 mg once daily orally in the evening (between 6:30 p.m. and 9:30 p.m.) as the starting dose for patients 6 years and older; titrate weekly in increments of 20 mg up to a maximum of 100 mg/day.
Contraindications
- Known hypersensitivity to amphetamine or other components of DYANAVEL XR
- Concomitant use or within 14 days of stopping MAOIs (including linezolid or intravenous methylene blue) due to risk of hypertensive crisis
- History of hypersensitivity to methylphenidate or other components of JORNAY PM
- Concomitant treatment with monoamine oxidase (MAO) inhibitors, or within 14 days following discontinuation of an MAO inhibitor
Adverse Reactions
Most common (>=2%) Epistaxis, allergic rhinitis, upper abdominal pain (in pediatric patients aged 6-12 years in controlled trial)
Serious Palpitations, tachycardia, elevated blood pressure, sudden death, myocardial infarction, psychotic episodes, overstimulation, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, anaphylaxis
Postmarketing Rhabdomyolysis, Raynaud's phenomenon, intestinal ischemia, dermatillomania, bruxism, formication, frequent or prolonged erections, alopecia
Most common (>=5%) Any insomnia, decreased appetite, headache, vomiting, nausea, psychomotor hyperactivity, affect lability or mood swings
Serious Hypersensitivity reactions (angioedema, anaphylaxis), hypertensive crisis with MAO inhibitors, serious cardiac events, psychiatric adverse reactions, priapism, peripheral vasculopathy including Raynaud's phenomenon, long-term suppression of growth in pediatric patients
Postmarketing Pancytopenia, thrombocytopenia, angina pectoris, bradycardia, severe hepatic injury, rhabdomyolysis, convulsion, serotonin syndrome, hallucinations, mania, priapism, alopecia, Raynaud's phenomenon
Pharmacology
Amphetamine is a non-catecholamine sympathomimetic amine CNS stimulant that blocks reuptake of norepinephrine and dopamine into the presynaptic neuron and increases release of these monoamines into the extraneuronal space; the mode of therapeutic action in ADHD is not known.
CNS stimulant; methylphenidate is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space, though the exact mode of therapeutic action in ADHD is not known.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Dyanavel Xr
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
Jornay Pm
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (1/12)
UnitedHealthcare
Dyanavel Xr
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Jornay Pm
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Dyanavel Xr
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Jornay Pm
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Dyanavel Xr.
No savings programs available for Jornay Pm.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Dyanavel XrView full Dyanavel Xr profile
Jornay PmView full Jornay Pm profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.